PL3663317T3 - Przeciwciała skierowane przeciwko haptenom kwetiapinowym i ich zastosowanie - Google Patents

Przeciwciała skierowane przeciwko haptenom kwetiapinowym i ich zastosowanie

Info

Publication number
PL3663317T3
PL3663317T3 PL20152974.0T PL20152974T PL3663317T3 PL 3663317 T3 PL3663317 T3 PL 3663317T3 PL 20152974 T PL20152974 T PL 20152974T PL 3663317 T3 PL3663317 T3 PL 3663317T3
Authority
PL
Poland
Prior art keywords
antibodies
quetiapine haptens
quetiapine
haptens
Prior art date
Application number
PL20152974.0T
Other languages
English (en)
Inventor
Eric Hryhorenko
Banumathi Sankaran
Thomas R. DECORY
Theresa TUBBS
Linda COLT
Bart M. REMMERIE
Rhys Salter
Matthew Garrett DONAHUE
Yong Gong
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PL3663317T3 publication Critical patent/PL3663317T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9466Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Psychiatry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL20152974.0T 2012-08-21 2013-08-20 Przeciwciała skierowane przeciwko haptenom kwetiapinowym i ich zastosowanie PL3663317T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261691598P 2012-08-21 2012-08-21

Publications (1)

Publication Number Publication Date
PL3663317T3 true PL3663317T3 (pl) 2023-06-05

Family

ID=50148312

Family Applications (3)

Application Number Title Priority Date Filing Date
PL18157667T PL3385284T3 (pl) 2012-08-21 2013-08-20 Przeciwciała skierowane przeciwko haptenom kwetiapinowym i ich zastosowanie
PL13830990T PL2888286T3 (pl) 2012-08-21 2013-08-20 Przeciwciała skierowane przeciwko haptenom kwetiapinowym i ich zastosowanie
PL20152974.0T PL3663317T3 (pl) 2012-08-21 2013-08-20 Przeciwciała skierowane przeciwko haptenom kwetiapinowym i ich zastosowanie

Family Applications Before (2)

Application Number Title Priority Date Filing Date
PL18157667T PL3385284T3 (pl) 2012-08-21 2013-08-20 Przeciwciała skierowane przeciwko haptenom kwetiapinowym i ich zastosowanie
PL13830990T PL2888286T3 (pl) 2012-08-21 2013-08-20 Przeciwciała skierowane przeciwko haptenom kwetiapinowym i ich zastosowanie

Country Status (10)

Country Link
US (3) US9850318B2 (pl)
EP (3) EP3663317B1 (pl)
JP (2) JP6450314B2 (pl)
CN (2) CN104736564B (pl)
AU (2) AU2013305904B2 (pl)
CA (1) CA2882597C (pl)
ES (3) ES2788716T3 (pl)
PL (3) PL3385284T3 (pl)
PT (3) PT2888286T (pl)
WO (1) WO2014031665A1 (pl)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1984487B1 (en) * 2005-08-03 2022-10-12 Astellas Institute for Regenerative Medicine Improved methods of reprogramming animal somatic cells
WO2013010045A1 (en) 2011-07-12 2013-01-17 Biotime Inc. Novel methods and formulations for orthopedic cell therapy
ES2870004T3 (es) 2012-08-21 2021-10-26 Janssen Pharmaceutica Nv Anticuerpos contra la risperidona y uso de los mismos
CN107253993B (zh) 2012-08-21 2021-10-22 詹森药业有限公司 奥氮平的抗体及其用途
TR201910347T4 (tr) 2012-08-21 2019-07-22 Janssen Pharmaceutica Nv Olanzapin haptenlerine yönelik antikorlar ve bunların kullanımı.
ES2788716T3 (es) * 2012-08-21 2020-10-22 Janssen Pharmaceutica Nv Anticuerpos para haptenos de quetiapina y uso de los mismos
EP2888285B1 (en) 2012-08-21 2024-04-17 Janssen Pharmaceutica NV Antibodies to aripiprazole haptens and use thereof
ES2762105T3 (es) 2012-08-21 2020-05-22 Janssen Pharmaceutica Nv Anticuerpos para aripiprazol y uso de los mismos
CA2882615C (en) 2012-08-21 2019-07-09 Ortho-Clinical Diagnostics, Inc. Antibodies to quetiapine and use thereof
EP2888284B1 (en) 2012-08-21 2022-07-06 Janssen Pharmaceutica NV Antibodies to risperidone haptens and use thereof
CN104736566A (zh) 2012-08-21 2015-06-24 奥索临床诊断有限公司 帕潘立酮半抗原的抗体及其用途
WO2014031584A1 (en) 2012-08-21 2014-02-27 Janssen Pharmaceutica Nv Haptens of aripiprazole and their use in immunoassays
HK1211958A1 (en) 2012-08-21 2016-06-03 Ortho-Clinical Diagnostics, Inc. Antibodies to paliperidone and use thereof
JP6994461B2 (ja) * 2015-12-17 2022-02-04 ヤンセン ファーマシューティカ エヌ.ベー. クエチアピンに対する抗体及びその使用
CA3008809A1 (en) 2015-12-17 2017-06-22 Janssen Pharmaceutica Nv Antibodies to risperidone and use thereof
CN110938082A (zh) * 2019-10-30 2020-03-31 杭州博拓生物科技股份有限公司 一种奥氮平人工抗原及其制备方法
CN111808046B (zh) * 2020-06-30 2022-11-11 杭州同舟生物技术有限公司 一种喹硫平人工半抗原、人工抗原及其制备方法和应用
CN115073492B (zh) * 2022-08-22 2022-11-18 北京丹大生物技术有限公司 一种奥氮平衍生物抗原、奥氮平抗体及其应用
CN116354904B (zh) * 2023-04-26 2023-08-01 北京丹大生物技术有限公司 一种喹硫平衍生物半抗原、抗原、抗喹硫平抗体及其应用

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
EP0560410B1 (en) 1987-04-27 2002-10-02 Inverness Medical Switzerland GmbH A test device for performing specific binding assays
US5120643A (en) 1987-07-13 1992-06-09 Abbott Laboratories Process for immunochromatography with colloidal particles
AU2684488A (en) 1988-06-27 1990-01-04 Carter-Wallace, Inc. Test device and method for colored particle immunoassay
US5252496A (en) 1989-12-18 1993-10-12 Princeton Biomeditech Corporation Carbon black immunochemical label
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
EP0582368B1 (en) 1992-05-29 2001-01-24 Eli Lilly And Company Limited Thienobenzodiazepine derivatives for treatment of CNS disorders
US6034078A (en) 1992-05-29 2000-03-07 Eli Lilly And Company Limited Thienobenzodiazepine compounds
US5642870A (en) 1992-08-05 1997-07-01 Sargis; Ike Switch stand
US5395933A (en) 1992-08-07 1995-03-07 Eastman Kodak Company Carbamazepine hapten analogues
JPH10504186A (ja) 1994-06-10 1998-04-28 オクラホマ メディカル リサーチ ファウンデーション プロテインcに対するカルシウム結合組換え抗体
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5761894A (en) 1996-09-25 1998-06-09 Magic Circle Corporation Grass striping attachment for lawn mowers
AU8148898A (en) 1997-06-23 1999-01-04 Luminex Corporation Interlaced lasers for multiple fluorescence measurement
US6830731B1 (en) 1998-01-05 2004-12-14 Biosite, Inc. Immunoassay fluorometer
US6541669B1 (en) 1998-06-08 2003-04-01 Theravance, Inc. β2-adrenergic receptor agonists
US20030143233A1 (en) 1999-06-07 2003-07-31 Neorx Corporation Streptavidin expressed gene fusions and methods of use thereof
US7163681B2 (en) * 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
US6958156B2 (en) 2000-12-15 2005-10-25 Vyrex Corporation Isoflavone derivatives
US7193065B2 (en) 2001-07-13 2007-03-20 Roche Diagnostics Operations, Inc. Protease inhibitor conjugates and antibodies useful in immunoassay
DE60335428D1 (de) * 2002-01-31 2011-02-03 Randox Lab Ltd Immunogene, Antikörper und Konjugate für Ketamin und dessen Metaboliten
JP2005526501A (ja) 2002-02-21 2005-09-08 デューク・ユニヴァーシティ 自己免疫疾患用の試薬および治療方法
EP2316468A1 (en) 2002-02-22 2011-05-04 Shire LLC Delivery system and methods for protecting and administering dextroamphetamine
US20050124704A1 (en) 2002-03-04 2005-06-09 Rasheed Ahmed A. Paper and materials and processes for its production
CA2479932A1 (en) 2002-03-28 2003-10-09 Eli Lilly And Company Piperazine substituted aryl benzodiazepines and their use as dopamine receptor antagonists for the treatment of psychotic disorders
SE0201738D0 (sv) 2002-06-07 2002-06-07 Aamic Ab Micro-fluid structures
US20040127489A1 (en) 2002-07-29 2004-07-01 David Pickar Novel antipsychotic combination therapies and compositions useful therein
PT1546134E (pt) 2002-08-05 2007-08-10 Lilly Co Eli ''arilbenzodiazepinas substituídas com piperazina''
KR101412271B1 (ko) 2003-05-09 2014-06-25 듀크 유니버시티 Cd20-특이적 항체 및 이를 이용한 방법
WO2005016901A1 (en) * 2003-08-18 2005-02-24 H. Lundbeck A/S Trans-1(6-chloro-3-phenylindan-1-yl)-3,3-dimethylpiperazine
PT1664007E (pt) 2003-09-23 2010-02-15 Fermion Oy Preparação de quetiapina
AU2004278414B2 (en) 2003-10-01 2012-05-24 Adolor Corporation Spirocyclic heterocyclic derivatives and methods of their use
PL1675573T4 (pl) 2003-10-23 2016-04-29 Otsuka Pharma Co Ltd Sterylny preparat do wstrzykiwań arypiprazolu o kontrolowanym uwalnianiu i sposób
AU2004298660B2 (en) * 2003-12-12 2010-04-22 Abbott Rapid Diagnostics International Unlimited Company Assay
SE0400662D0 (sv) 2004-03-24 2004-03-24 Aamic Ab Assay device and method
EP1748070A4 (en) 2004-04-26 2007-07-18 Takami Matsuyama THERAPEUTIC WITH MONOCLONAL ANTIBODY AGAINST FOLAT RECEPTOR BETA (FR-BETA)
US7087699B2 (en) 2004-05-17 2006-08-08 Acushnet Company Sulfur-containing composition for golf equipment, and method of using same
SE527036C2 (sv) 2004-06-02 2005-12-13 Aamic Ab Analysanordning med reglerat flöde och motsvarande förfarande
TW200616604A (en) 2004-08-26 2006-06-01 Nicholas Piramal India Ltd Nitric oxide releasing prodrugs containing bio-cleavable linker
FR2878850B1 (fr) 2004-12-02 2008-10-31 Cis Bio Internat Sa Derives de l'inositol-1-phosphate
US20060235005A1 (en) 2005-04-14 2006-10-19 Oak Labs, Corp. Use of phosphodiesterase 5 (PDE5) inhibitors in the treatment of schizophrenia
SE529254C2 (sv) 2005-06-17 2007-06-12 Aamic Ab Optiskt testsystem
SE528233C2 (sv) 2005-06-20 2006-09-26 Aamic Ab Metod och medel för att åstadkomma vätsketransport
SE529711C2 (sv) 2006-03-22 2007-11-06 Aamic Ab Fluorescensläsare
US8975374B2 (en) 2006-10-20 2015-03-10 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition comprising anti-HB-EGF antibody as active ingredient
EP2077860B1 (en) * 2006-10-25 2014-04-09 Ramot at Tel-Aviv University Ltd Psychotropic agents having glutamate nmda activity
DK3564674T3 (da) * 2006-11-01 2021-10-18 Ventana Med Syst Inc Haptener, haptenkonjugater, sammensætninger deraf og fremgangsmåde til fremstilling og anvendelse deraf
US20080138842A1 (en) * 2006-12-11 2008-06-12 Hans Boehringer Indirect lateral flow sandwich assay
CA2672972C (en) 2006-12-29 2015-06-23 Abbott Laboratories Diagnostic test for the detection of a molecule or drug in whole blood
CN100482643C (zh) * 2007-01-19 2009-04-29 中国科学院广州生物医药与健康研究院 一种氨基脲衍生物及其单克隆抗体与应用
CN101091700B (zh) * 2007-07-03 2011-06-08 上海现代药物制剂工程研究中心有限公司 富马酸喹硫平缓控释制剂组合物及其制备用途
MX2010003259A (es) 2007-09-27 2010-04-12 Novartis Ag Ensayo de monitoreo de farmacos.
EA028427B1 (ru) 2008-07-21 2017-11-30 Пробиодруг Аг АНТИТЕЛО, СВЯЗЫВАЮЩЕЕСЯ С Aβ-ПЕПТИДАМИ ИЛИ ИХ ВАРИАНТАМИ, КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ЭТО АНТИТЕЛО, И ЕГО ПРИМЕНЕНИЕ
CN102170874A (zh) * 2008-08-06 2011-08-31 高思福斯中心(控股)有限公司 治疗精神病学障碍的组合物和方法
US20100069356A1 (en) 2008-09-17 2010-03-18 Auspex Pharmaceuticals, Inc. Dibenzothiazepine modulators of dopamine, alpha adrenergic, and serotonin receptors
UY32174A (es) 2008-10-14 2010-05-31 Astrazeneca Ab Nuevos heterociclos sustituidos, composiciones farmaceuticas conteniendolos, procedimientos de preparacion y aplicaciones
CA2742074A1 (en) * 2008-10-29 2010-08-26 Janssen Pharmaceutica Nv Methods of treating psychosis and schizophrenia based on polymorphisms in the erbb4 gene
EP2194048A1 (en) 2008-12-02 2010-06-09 Dirk Sartor Nitrate esters for the treatment of vascular and metabolic diseases
US8480333B2 (en) 2008-12-26 2013-07-09 Steven Edward DeMay Frame rail assemblies and interlocking frame rail systems
CA2750400A1 (en) 2009-01-26 2010-07-29 Egalet A/S Controlled release formulations with continuous efficacy
CA2754743C (en) 2009-03-10 2020-08-25 Baylor Research Institute Antigen presenting cell targeted anti-viral vaccines
CN104586859B (zh) * 2009-12-31 2017-12-05 凯姆制药公司 喹硫平的氨基酸缀合物、其制备和使用方法
DK2544536T3 (en) * 2010-03-11 2019-02-04 Kempharm Inc FAT ACID CONJUGATES OF QUETIAPIN, METHOD OF PREPARING IT AND USING IT
US8088594B2 (en) 2010-03-16 2012-01-03 Saladax Biomedical Inc. Risperidone immunoassay
WO2011159537A2 (en) * 2010-06-15 2011-12-22 The Regents Of The University Of California Method and device for analyte detection
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
US8913245B2 (en) 2010-06-29 2014-12-16 Kla-Tencor Corporation System and method for interferometric autofocusing
WO2012003418A2 (en) 2010-07-02 2012-01-05 The University Of North Carolina At Chapel Hill Functionally selective ligands of dopamine d2 receptors
US8623324B2 (en) 2010-07-21 2014-01-07 Aat Bioquest Inc. Luminescent dyes with a water-soluble intramolecular bridge and their biological conjugates
CN102190724A (zh) * 2011-03-31 2011-09-21 上海大学 十氯酮抗原、抗体及其制备方法
US8969337B2 (en) 2011-12-15 2015-03-03 Alkermes Pharma Ireland Limited Prodrugs of secondary amine compounds
SG11201501130PA (en) 2012-08-16 2015-04-29 Janssen Pharmaceutica Nv Substituted pyrazoles as n-type calcium channel blockers
AU2013305936B2 (en) 2012-08-21 2017-08-03 Saladax Biomedical Inc. Haptens of risperidone and paliperidone
PL2888258T3 (pl) 2012-08-21 2019-10-31 Janssen Pharmaceutica Nv Hapteny paliperydonu
TR201910347T4 (tr) 2012-08-21 2019-07-22 Janssen Pharmaceutica Nv Olanzapin haptenlerine yönelik antikorlar ve bunların kullanımı.
CN104736566A (zh) 2012-08-21 2015-06-24 奥索临床诊断有限公司 帕潘立酮半抗原的抗体及其用途
EP2888284B1 (en) 2012-08-21 2022-07-06 Janssen Pharmaceutica NV Antibodies to risperidone haptens and use thereof
CN107253993B (zh) 2012-08-21 2021-10-22 詹森药业有限公司 奥氮平的抗体及其用途
PT3305784T (pt) 2012-08-21 2020-10-23 Janssen Pharmaceutica Nv Haptenos de quetiapina para utilização em ensaios imunológicos
HK1211958A1 (en) 2012-08-21 2016-06-03 Ortho-Clinical Diagnostics, Inc. Antibodies to paliperidone and use thereof
ES2870004T3 (es) 2012-08-21 2021-10-26 Janssen Pharmaceutica Nv Anticuerpos contra la risperidona y uso de los mismos
US9303041B2 (en) 2012-08-21 2016-04-05 Janssen Pharmaceutica Nv Haptens of olanzapine
WO2014031584A1 (en) 2012-08-21 2014-02-27 Janssen Pharmaceutica Nv Haptens of aripiprazole and their use in immunoassays
ES2788716T3 (es) * 2012-08-21 2020-10-22 Janssen Pharmaceutica Nv Anticuerpos para haptenos de quetiapina y uso de los mismos
ES2762105T3 (es) 2012-08-21 2020-05-22 Janssen Pharmaceutica Nv Anticuerpos para aripiprazol y uso de los mismos
EP2888285B1 (en) 2012-08-21 2024-04-17 Janssen Pharmaceutica NV Antibodies to aripiprazole haptens and use thereof
CA2882615C (en) 2012-08-21 2019-07-09 Ortho-Clinical Diagnostics, Inc. Antibodies to quetiapine and use thereof
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
JP6994461B2 (ja) * 2015-12-17 2022-02-04 ヤンセン ファーマシューティカ エヌ.ベー. クエチアピンに対する抗体及びその使用

Also Published As

Publication number Publication date
CA2882597A1 (en) 2014-02-27
ES2788716T3 (es) 2020-10-22
JP6637580B2 (ja) 2020-01-29
PT3385284T (pt) 2020-05-20
US9850318B2 (en) 2017-12-26
US20210017294A9 (en) 2021-01-21
EP2888286B1 (en) 2018-02-21
AU2013305904A1 (en) 2015-03-05
CN104736564B (zh) 2019-02-05
US20140057305A1 (en) 2014-02-27
CA2882597C (en) 2020-04-14
US20180105606A1 (en) 2018-04-19
ES2935460T3 (es) 2023-03-07
EP3663317A1 (en) 2020-06-10
HK1211959A1 (en) 2016-06-03
AU2017261579A1 (en) 2017-12-07
EP3385284A1 (en) 2018-10-10
EP3385284B1 (en) 2020-02-26
EP2888286A1 (en) 2015-07-01
PT3663317T (pt) 2023-01-23
EP3663317B1 (en) 2022-10-12
JP2019073513A (ja) 2019-05-16
CN110054693A (zh) 2019-07-26
ES2664952T3 (es) 2018-04-24
PT2888286T (pt) 2018-05-09
JP2015529203A (ja) 2015-10-05
CN104736564A (zh) 2015-06-24
US20200040107A1 (en) 2020-02-06
AU2017261579B2 (en) 2019-11-07
EP2888286A4 (en) 2016-03-23
PL3385284T3 (pl) 2020-09-21
WO2014031665A1 (en) 2014-02-27
AU2013305904B2 (en) 2017-08-17
US10465013B2 (en) 2019-11-05
PL2888286T3 (pl) 2018-07-31
JP6450314B2 (ja) 2019-01-09

Similar Documents

Publication Publication Date Title
PT3385284T (pt) Anticorpos para haptenos de quetiapina e sua utilização
PT2888284T (pt) Anticorpos dirigidos contra haptenos de risperidona e a sua utilização
PT2887952T (pt) Anticorpos para haptenos da olanzapina e suas utilizações
PT2888592T (pt) Anticorpos contra a quetiapina e sua utilização
IL238559A0 (en) Antibodies against ceacam5 and their use
PL3462173T3 (pl) Przeciwciała przeciwko rysperydonowi i ich zastosowanie
EP2888287A4 (en) ANTIBODIES AGAINST PALIPERIDONE HAPTENES AND THEIR USE
PL2888257T3 (pl) Hapteny kwetiapiny do zastosowania w testach immunologicznych
PT2888590T (pt) Anticorpos para olanzapina e utilização destes
IL254416B (en) Anti-asic1 antibodies and their uses
PT3354751T (pt) Anticorpos contra aripiprazole e seu uso
EP2888277A4 (en) ANTIBODIES AGAINST PALIPERIDONE AND USE THEREOF
IL238366A0 (en) Antibodies to interleukin-6 and their uses
GB201208372D0 (en) Antibodies and uses thereof